Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.

Department of Pharmacology, Vanderbilt Program in Drug Discovery, Vanderbilt Medical Center, Nashville, TN 37232, USA.
Trends in Pharmacological Sciences (Impact Factor: 9.99). 03/2009; 30(3):148-55. DOI: 10.1016/
Source: PubMed

ABSTRACT Muscarinic acetylcholine receptors (mAChRs) have long been viewed as viable targets for novel therapeutic agents for the treatment of Alzheimer's disease (AD) and other disorders involving impaired cognitive function. More recent evidence indicates that mAChR activators might also have utility in treating psychosis and other symptoms associated with schizophrenia and other central nervous system (CNS) disorders. Efforts to develop mAChR subtype-selective agonists have been hampered by difficulty in achieving high selectivity for individual mAChR subtypes important for CNS function (M(1) and M(4)) and adverse effects due to activation of peripheral mAChRs (especially M(2) and M(3)). Major advances have now been achieved in the discovery of allosteric agonists and positive allosteric modulators of M(1) and M(4) that show greater selectivity for individual mAChR subtypes than do previous mAChR agonists. Early studies indicate that these allosteric mAChR activators have properties needed for optimization as potential clinical candidates and have robust effects in animal models that predict efficacy in the treatment of AD, schizophrenia and related disorders.

  • [Show abstract] [Hide abstract]
    ABSTRACT: This Letter describes the continued optimization of the MLPCN probe ML375, a highly selective M5 negative allosteric modulator (NAM), through a combination of matrix libraries and iterative parallel synthesis. True to certain allosteric ligands, SAR was shallow, and the matrix library approach highlighted the challenges with M5 NAM SAR within in this chemotype. Once again, enantiospecific activity was noted, and potency at rat and human M5 were improved over ML375, along with slight enhancement in physiochemical properties, certain in vitro DMPK parameters and CNS distribution. Attempts to further enhance pharmacokinetics with deuterium incorporation afforded mixed results, but pretreatment with a pan-P450 inhibitor (1-aminobenzotriazole; ABT) provided increased plasma exposure. Copyright © 2014 Elsevier Ltd. All rights reserved.
    Bioorganic & Medicinal Chemistry Letters 12/2014; 25(3). DOI:10.1016/j.bmcl.2014.11.082 · 2.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A simple, sensitive and selective high performance liquid chromatography method has been developed and validated for the estimation of benzyl quinolone carboxylic acid (BQCA) in Sprague-Dawley (SD) rat plasma and tissue samples. Plasma and tissue samples were extracted by a protein precipitation technique using methanol as a precipitating agent and donepezil as the internal standard. Chromatographic separation was performed on a Hibar C18 column with a mobile phase of acetonitrile and potassium dihydrogen orthophosphate buffer (20 mM, pH 6.5) at a flow rate of 0.8 mL min−1. The lower limit of quantitation of the developed method was found to be 2.0 ng mL−1 and 5.0 ng g−1 for plasma and tissue samples, respectively. Following intraperitoneal (i.p.) administration, BQCA was remarkably absorbed into the systemic circulation with maximum concentration (8000.0 ng mL−1) within 1.5 h. The order of the area under the curve results from the tissue distribution study was kidney > lung > liver > brain > spleen > heart. BQCA was rapidly taken up into the brain resulting in a maximal brain concentration after 1.5 h which was maintained for up to 3-4 h. The method was successfully applied in the analysis of BQCA in plasma and tissue samples following i.p. administration to SD rats at a dose of 10 mg kg−1.
    Analytical methods 01/2014; 6(8):2672. DOI:10.1039/c4ay00102h · 1.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Benzylquinolone carboxylic acid (BQCA) is the first highly selective positive allosteric modulator (PAM) for the M1 muscarinic acetylcholine receptor (mAChR), but possesses low affinity for the allosteric site on the receptor. More recent drug discovery efforts identified 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one (referred to herein as benzoquinazolinone 12) as a more potent M1 mAChR PAM with a structural ancestry originating from BQCA and related compounds. In the current study, we optimized the synthesis of and fully characterized the pharmacology of benzoquinazolinone 12, finding that its improved potency derived from a 50-fold increase in allosteric site affinity as compared to BQCA, while retaining a similar level of positive cooperativity with acetylcholine (ACh). We then utilized site-directed mutagenesis and molecular modeling to validate the allosteric binding pocket we previously described for BQCA as a shared site for benzoquinazolinone 12, and provide a molecular basis for its improved activity at the M1 mAChR. This includes a key role for hydrophobic and polar interactions with residues Tyr179, in the second extracellular loop (ECL2), and Trp400(7.35) in transmembrane (TM) domain 7. Collectively, this study highlights how the properties of affinity and cooperativity can be differentially modified on a common structural scaffold, and identifies molecular features that can be exploited to tailor the development of M1 mAChR-targeting PAMs.
    Journal of Biological Chemistry 10/2014; DOI:10.1074/jbc.M114.604967 · 4.60 Impact Factor

Full-text (2 Sources)

Available from
May 16, 2014